BioCentury | Apr 1, 2020
Finance

Reversing course on IPO plans, iTeos draws $125M in private round with crossovers

With two programs having entered the clinic since the company’s series B round, iTeos chose to raise another large private round rather than seek to tap the public markets as it had expected, drawing a...
BC Week In Review | Jun 22, 2018
Financial News

Oncology play iTeos raises $75M, outlines clinical plans

iTeos Therapeutics S.A. (Gosselies, Belgium) raised $75 million on June 19 in a series B round led by MPM Capital. Also participating in the round were HBM Partners, 6 Dimensions Capital, Curative Ventures and SFPI...
BC Extra | Jun 20, 2018
Financial News

Oncology play iTeos raises $75M, outlines clinical plans

iTeos Therapeutics S.A. (Gosselies, Belgium) raised $75 million in a series B round led by MPM Capital. Also participating in the round were HBM Partners, 6 Dimensions Capital, Curative Ventures and SFPI as well as...
BioCentury | Jun 20, 2018
Finance

Iterating iTeos

With a new office in the U.S. and $75 million in fresh series B funding to support clinical development of at least two candidates, Belgian cancer company iTeos Therapeutics S.A. is considering a U.S. IPO...
BioCentury | Mar 24, 2018
Product Development

Optimism for A2A

Once considered solely a neurology target, the adenosine pathway has attracted interest in immuno-oncology based on its ability to control whether immune cells adopt a stimulatory or suppressive phenotype. The early results from A2A receptor...
Items per page:
1 - 5 of 5